Evidence map›Paper›PMID 32977498›Full record

ArticleBiomolecules2020

Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.

Péter Hollósi, Lóránd Váncza, Katalin Karászi, Katalin Dobos, Bálint Péterfia, Enikő Tátrai, Péter Tátrai, Tibor Szarvas, Sándor Paku, László Szilák and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Péter HollósiFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Lóránd VánczaFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.ORCID 0000-0003-0295-4732
Katalin KarásziFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.ORCID 0000-0002-9188-1987
Katalin DobosFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Bálint PéterfiaFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Enikő TátraiFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Péter TátraiFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.ORCID 0000-0001-9726-1992
Tibor SzarvasFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Sándor PakuFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
László SzilákSzilak Laboratories Bioinformatics and Molecule-Design Ltd., Gem utca 14, H-6723 Szeged, Hungary.
Ilona KovalszkyFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.ORCID 0000-0002-0179-3378
Semmelweis University · HU

Funding

European Social Fund EFOP-3.6.3-VEKOP-16-2017-00009H2020 Marie Skłodowska-Curie Actions 645756 GLYCANCHungarian Scientific Research Fund 100904Hungarian Scientific Research Fund 119283Hungarian Scientific Research Fund 67925
6 · The paper itself

Abstract

Syndecan-1 is a transmembrane heparan sulfate proteoglycan which is indispensable in the structural and functional integrity of epithelia. Normal hepatocytes display strong cell surface expression of syndecan-1; however, upon malignant transformation, they may lose it from their cell surfaces. In this study, we demonstrate that re-expression of full-length or ectodomain-deleted syndecan-1 in hepatocellular carcinoma cells downregulates phosphorylation of ERK1/2 and p38, with the truncated form exerting an even stronger effect than the full-length protein. Furthermore, overexpression of syndecan-1 in hepatoma cells is associated with a shift of heparan sulfate structure toward a highly sulfated type specific for normal liver. As a result, cell proliferation and proteolytic shedding of syndecan-1 from the cell surface are restrained, which facilitates redifferentiation of hepatoma cells to a more hepatocyte-like phenotype. Our results highlight the importance of syndecan-1 in the formation and maintenance of differentiated epithelial characteristics in hepatocytes partly via the HGF/ERK/Ets-1 signal transduction pathway. Downregulation of Ets-1 expression alone, however, was not sufficient to replicate the phenotype of syndecan-1 overexpressing cells, indicating the need for additional molecular mechanisms. Accordingly, a reporter gene assay revealed the inhibition of Ets-1 as well as AP-1 transcription factor-induced promoter activation, presumably an effect of the heparan sulfate switch.

Indexed as

Carcinoma, HepatocellularCell DifferentiationCell ProliferationGene Expression Regulation, NeoplasticHeparan SulfateHepatocyte Growth FactorHepatocytesHep G2 CellsHumansLiver NeoplasmsMAP Kinase Signaling SystemProto-Oncogene Protein c-ets-1Signal TransductionSyndecan-1Transcription Factor AP-1ETS1 protein, humanHeparan SulfateHepatocyte Growth FactorHGF protein, humanProto-Oncogene Protein c-ets-1Syndecan-1Transcription Factor AP-1AP-1differentiationepitheliumEts-1heparan sulfateliver cancerMMP-7sheddingsyndecan-1

Identifiers

PMID32977498
PMCPMC7598270
OpenAlexW3088954717

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.